patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_734592 | REC_0002901 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 9.4 | 71 | female | 0 | 19 | 4.2 | 8 | osimertinib 80 mg daily | 7.1 | true | MSS | 2026-03-15T05:35:57.559491+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_394856 | REC_0002902 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 20 | 5.3 | 71 | male | 1 | 10 | 5.2 | 0 | pembrolizumab 200 mg q3w | 59.8 | true | MSS | 2026-03-15T05:35:57.559733+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_214004 | REC_0002903 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 16.8 | 72 | male | 2 | 10 | 4.3 | 1 | alectinib 600 mg BID | 18.4 | true | MSI-H | 2026-03-15T05:35:57.559977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244355 | REC_0002904 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 17.8 | 60 | male | 1 | 11 | 5.9 | 6 | osimertinib 80 mg daily | 9.7 | false | MSI-H | 2026-03-15T05:35:57.560388+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_503054 | REC_0002905 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 15 | 16.1 | 70 | female | 1 | 13 | 5.5 | 0 | osimertinib 80 mg daily | 42.6 | false | MSS | 2026-03-15T05:35:57.560653+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306746 | REC_0002906 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 5.4 | 76 | female | 0 | 0 | 6.3 | 5 | pembrolizumab 200 mg q3w | 7 | false | MSS | 2026-03-15T05:35:57.560891+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_637046 | REC_0002907 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 11.1 | 58 | female | 1 | 10 | 4.3 | 5 | entrectinib 600 mg daily | 12.1 | true | MSS | 2026-03-15T05:35:57.561134+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955742 | REC_0002908 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 5.9 | 73 | female | 1 | 44 | 4.7 | 6 | pembrolizumab 200 mg q3w | 18.5 | true | MSS | 2026-03-15T05:35:57.561368+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_256503 | REC_0002909 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 6.2 | 53 | female | 0 | 48 | 7.7 | 9 | carboplatin + paclitaxel + pembrolizumab | 8.5 | true | MSS | 2026-03-15T05:35:57.561603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267527 | REC_0002910 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 19.6 | 55 | male | 0 | 26 | 5.7 | 5 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:57.561839+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_230506 | REC_0002911 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 12.1 | 70 | female | 1 | 19 | 6.7 | 2 | osimertinib 80 mg daily | 17.1 | false | MSI-H | 2026-03-15T05:35:57.562075+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_114056 | REC_0002912 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 7.9 | 62 | female | 0 | 21 | 6 | 2 | sotorasib 960 mg daily | 11.6 | false | MSS | 2026-03-15T05:35:57.562307+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899113 | REC_0002913 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 7.8 | 63 | female | 1 | 50 | 6.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 25.6 | false | MSS | 2026-03-15T05:35:57.562640+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_268382 | REC_0002914 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 18 | 7.4 | 74 | female | 2 | 55 | 4.9 | 1 | pembrolizumab 200 mg q3w | 33.5 | false | MSS | 2026-03-15T05:35:57.562874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553295 | REC_0002915 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 3.9 | 68 | female | 0 | 49 | 6.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 5.7 | true | MSS | 2026-03-15T05:35:57.563107+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_833811 | REC_0002916 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 15.9 | 66 | male | 0 | 20 | 5 | 2 | sotorasib 960 mg daily | 15.6 | false | MSI-H | 2026-03-15T05:35:57.563343+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_671369 | REC_0002917 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 14.6 | 73 | female | 1 | 17 | 4.7 | 6 | entrectinib 600 mg daily | 10.4 | false | MSI-H | 2026-03-15T05:35:57.563575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201225 | REC_0002918 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 11.6 | 64 | female | 0 | 10 | 6.6 | 4 | osimertinib 80 mg daily | 14.9 | true | MSS | 2026-03-15T05:35:57.563814+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_496067 | REC_0002919 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 20 | 6.3 | 63 | male | 0 | 11 | 6.8 | 2 | pembrolizumab 200 mg q3w | 26.1 | false | MSS | 2026-03-15T05:35:57.564049+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393056 | REC_0002920 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 9.8 | 63 | female | 1 | 12 | 5.6 | 5 | osimertinib 80 mg daily | 11.2 | true | MSS | 2026-03-15T05:35:57.564329+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_742246 | REC_0002921 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 16.2 | 75 | female | 1 | 23 | 6 | 5 | alectinib 600 mg BID | 13.6 | false | MSS | 2026-03-15T05:35:57.564570+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395681 | REC_0002922 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 14 | 9.5 | 71 | female | 1 | 3 | 3.8 | 4 | entrectinib 600 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:57.564800+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_441154 | REC_0002923 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 7.3 | 63 | female | 1 | 10 | 4.6 | 2 | osimertinib 80 mg daily | 6.2 | true | MSS | 2026-03-15T05:35:57.565037+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324980 | REC_0002924 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 13.7 | 56 | male | 0 | 18 | 4 | 1 | alectinib 600 mg BID | 14.9 | false | MSI-H | 2026-03-15T05:35:57.565274+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_265025 | REC_0002925 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 5 | 70 | female | 2 | 60 | 5 | 1 | carboplatin + paclitaxel + pembrolizumab | 23 | false | MSS | 2026-03-15T05:35:57.565503+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_131102 | REC_0002926 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 5.5 | 69 | female | 1 | 48 | 6.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.7 | false | MSS | 2026-03-15T05:35:57.565786+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449316 | REC_0002927 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 18.2 | 68 | female | 1 | 6 | 4.8 | 8 | osimertinib 80 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:57.566027+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_800974 | REC_0002928 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 19.1 | 62 | male | 1 | 13 | 3.8 | 7 | sotorasib 960 mg daily | 15.4 | false | MSI-H | 2026-03-15T05:35:57.566262+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_784369 | REC_0002929 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 4 | 71 | female | 2 | 19 | 4.1 | 7 | pembrolizumab 200 mg q3w | 13.2 | true | MSS | 2026-03-15T05:35:57.566493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_415350 | REC_0002930 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 9.5 | 78 | female | 1 | 52 | 6.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 6.8 | true | MSS | 2026-03-15T05:35:57.566719+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_280938 | REC_0002931 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 9.2 | 61 | female | 1 | 9 | 5.5 | 7 | sotorasib 960 mg daily | 9 | true | MSS | 2026-03-15T05:35:57.566952+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_470693 | REC_0002932 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 7.6 | 68 | female | 0 | 18 | 5.2 | 5 | sotorasib 960 mg daily | 5.3 | false | MSS | 2026-03-15T05:35:57.567179+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862726 | REC_0002933 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 8.1 | 62 | female | 1 | 21 | 5.5 | 7 | osimertinib 80 mg daily | 9.8 | false | MSS | 2026-03-15T05:35:57.567413+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_946873 | REC_0002934 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 16.8 | 60 | male | 1 | 15 | 7.2 | 2 | entrectinib 600 mg daily | 9.3 | true | MSI-H | 2026-03-15T05:35:57.567647+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_882648 | REC_0002935 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 6.2 | 65 | male | 1 | 2 | 6.2 | 6 | entrectinib 600 mg daily | 10.7 | true | MSS | 2026-03-15T05:35:57.567878+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_176404 | REC_0002936 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 18.5 | 76 | female | 0 | 11 | 2.7 | 2 | entrectinib 600 mg daily | 13.9 | false | MSI-H | 2026-03-15T05:35:57.568207+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_646007 | REC_0002937 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 8.5 | 65 | female | 1 | 17 | 7 | 5 | osimertinib 80 mg daily | 6.8 | false | MSS | 2026-03-15T05:35:57.568455+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_179538 | REC_0002938 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 34 | 4 | 71 | female | 1 | 13 | 5.1 | 5 | pembrolizumab 200 mg q3w | 13.3 | false | MSS | 2026-03-15T05:35:57.568686+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_958898 | REC_0002939 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 21.1 | 70 | female | 1 | 8 | 2 | 8 | entrectinib 600 mg daily | 20.1 | false | MSI-H | 2026-03-15T05:35:57.568983+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_562535 | REC_0002940 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 15.1 | 67 | female | 1 | 21 | 5.3 | 8 | osimertinib 80 mg daily | 10 | false | MSS | 2026-03-15T05:35:57.569239+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_508349 | REC_0002941 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 25 | 10.8 | 57 | male | 1 | 16 | 5.2 | 0 | osimertinib 80 mg daily | 34.5 | true | MSI-H | 2026-03-15T05:35:57.569527+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_217659 | REC_0002942 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 16.7 | 77 | female | 2 | 19 | 7.8 | 2 | osimertinib 80 mg daily | 16 | true | MSS | 2026-03-15T05:35:57.569801+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753693 | REC_0002943 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 35 | 12.4 | 56 | male | 0 | 17 | 3.8 | 2 | entrectinib 600 mg daily | 12.3 | false | MSI-H | 2026-03-15T05:35:57.570050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_315901 | REC_0002944 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 28 | 6.2 | 58 | male | 0 | 60 | 6.5 | 1 | pembrolizumab 200 mg q3w | 26 | true | MSS | 2026-03-15T05:35:57.570290+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_754514 | REC_0002945 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 4.8 | 65 | female | 1 | 43 | 5.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 21.6 | true | MSS | 2026-03-15T05:35:57.570534+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_516801 | REC_0002946 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 12.1 | 57 | male | 0 | 25 | 3.7 | 1 | osimertinib 80 mg daily | 28.4 | true | MSS | 2026-03-15T05:35:57.570771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_176541 | REC_0002947 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 14.8 | 73 | male | 0 | 16 | 5 | 4 | osimertinib 80 mg daily | 18 | true | MSI-H | 2026-03-15T05:35:57.571008+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_191488 | REC_0002948 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 19.3 | 65 | male | 1 | 8 | 5.9 | 6 | osimertinib 80 mg daily | 12.8 | true | MSI-H | 2026-03-15T05:35:57.571247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_313498 | REC_0002949 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 16.3 | 67 | male | 0 | 12 | 5.6 | 7 | pembrolizumab 200 mg q3w | 15 | false | MSI-H | 2026-03-15T05:35:57.571484+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976301 | REC_0002950 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 16.1 | 77 | female | 1 | 13 | 3 | 2 | osimertinib 80 mg daily | 14.6 | false | MSI-H | 2026-03-15T05:35:57.571717+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_949662 | REC_0002951 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 11.6 | 68 | female | 0 | 12 | 3.6 | 1 | alectinib 600 mg BID | 9.9 | true | MSS | 2026-03-15T05:35:57.571950+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_688727 | REC_0002952 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 11.5 | 58 | female | 0 | 21 | 6.1 | 5 | entrectinib 600 mg daily | 10.4 | false | MSI-H | 2026-03-15T05:35:57.572374+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_514425 | REC_0002953 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 15.6 | 57 | female | 0 | 13 | 5.4 | 5 | alectinib 600 mg BID | 9.6 | true | MSS | 2026-03-15T05:35:57.572623+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865576 | REC_0002954 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 7.9 | 71 | female | 1 | 6 | 3.8 | 3 | entrectinib 600 mg daily | 10.6 | true | MSS | 2026-03-15T05:35:57.572854+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_581821 | REC_0002955 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 12 | 75 | female | 2 | 21 | 7.6 | 8 | sotorasib 960 mg daily | 7.1 | true | MSS | 2026-03-15T05:35:57.573089+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_920720 | REC_0002956 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 17.4 | 66 | female | 1 | 3 | 6.1 | 6 | sotorasib 960 mg daily | 10.6 | false | MSI-H | 2026-03-15T05:35:57.573318+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_239636 | REC_0002957 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 7.7 | 75 | female | 2 | 45 | 5.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 17.1 | false | MSS | 2026-03-15T05:35:57.573547+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_224450 | REC_0002958 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 14.8 | 77 | female | 2 | 11 | 5.7 | 5 | entrectinib 600 mg daily | 13.7 | false | MSI-H | 2026-03-15T05:35:57.573781+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_282845 | REC_0002959 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 18 | 50 | male | 0 | 14 | 6.3 | 4 | sotorasib 960 mg daily | 10.9 | false | MSI-H | 2026-03-15T05:35:57.574018+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_965092 | REC_0002960 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 8.7 | 65 | male | 1 | 15 | 6.1 | 9 | osimertinib 80 mg daily | 18.7 | false | MSS | 2026-03-15T05:35:57.574248+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_188555 | REC_0002961 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 12.4 | 57 | male | 1 | 22 | 4.8 | 5 | alectinib 600 mg BID | 10.3 | false | MSS | 2026-03-15T05:35:57.574483+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_114939 | REC_0002962 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 20 | 10.4 | 81 | female | 2 | 22 | 4.4 | 0 | sotorasib 960 mg daily | 50.6 | false | MSI-H | 2026-03-15T05:35:57.574718+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_657530 | REC_0002963 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 15.2 | 65 | male | 1 | 15 | 6.5 | 4 | osimertinib 80 mg daily | 8.4 | true | MSI-H | 2026-03-15T05:35:57.574955+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_325894 | REC_0002964 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 17.5 | 67 | female | 1 | 8 | 3 | 6 | alectinib 600 mg BID | 9.9 | false | MSS | 2026-03-15T05:35:57.575191+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_515340 | REC_0002965 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 37 | 12.4 | 57 | female | 0 | 11 | 4.6 | 2 | alectinib 600 mg BID | 15.7 | false | MSI-H | 2026-03-15T05:35:57.575482+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_424630 | REC_0002966 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 14.5 | 82 | female | 2 | 8 | 4.8 | 2 | entrectinib 600 mg daily | 24.4 | true | MSI-H | 2026-03-15T05:35:57.575719+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739722 | REC_0002967 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 16.3 | 69 | female | 1 | 13 | 5.3 | 7 | entrectinib 600 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:57.575957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109021 | REC_0002968 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 15 | 8.2 | 63 | female | 0 | 20 | 4.7 | 0 | carboplatin + paclitaxel + pembrolizumab | 34.4 | false | MSS | 2026-03-15T05:35:57.576283+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450002 | REC_0002969 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 20 | 7.5 | 60 | female | 1 | 20 | 6 | 0 | sotorasib 960 mg daily | 45.1 | false | MSS | 2026-03-15T05:35:57.576524+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244968 | REC_0002970 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 9.2 | 64 | female | 1 | 18 | 6.4 | 2 | entrectinib 600 mg daily | 38.1 | false | MSS | 2026-03-15T05:35:57.576758+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_268020 | REC_0002971 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 9.6 | 63 | male | 0 | 15 | 4.4 | 1 | osimertinib 80 mg daily | 15.2 | false | MSS | 2026-03-15T05:35:57.576994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167851 | REC_0002972 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 27 | 7.3 | 68 | male | 1 | 67 | 5 | 0 | carboplatin + paclitaxel + pembrolizumab | 20.4 | true | MSS | 2026-03-15T05:35:57.577229+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_973516 | REC_0002973 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 5.8 | 70 | female | 1 | 50 | 3.8 | 3 | carboplatin + paclitaxel + pembrolizumab | 18.5 | false | MSS | 2026-03-15T05:35:57.577458+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858920 | REC_0002974 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 8.8 | 69 | male | 1 | 26 | 5.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 16.1 | false | MSS | 2026-03-15T05:35:57.577692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_536260 | REC_0002975 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 15.2 | 75 | female | 2 | 9 | 4.1 | 5 | pembrolizumab 200 mg q3w | 9.1 | true | MSS | 2026-03-15T05:35:57.577924+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755373 | REC_0002976 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 6.9 | 73 | female | 1 | 47 | 6.3 | 3 | pembrolizumab 200 mg q3w | 9 | true | MSS | 2026-03-15T05:35:57.578152+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434434 | REC_0002977 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 29 | 14 | 77 | female | 2 | 14 | 5 | 0 | osimertinib 80 mg daily | 53.7 | false | MSI-H | 2026-03-15T05:35:57.578384+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_340340 | REC_0002978 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 11.9 | 73 | female | 0 | 16 | 4.5 | 6 | osimertinib 80 mg daily | 16.2 | false | MSI-H | 2026-03-15T05:35:57.578665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_984611 | REC_0002979 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 6.8 | 69 | female | 1 | 24 | 5.9 | 6 | pembrolizumab 200 mg q3w | 8.9 | false | MSS | 2026-03-15T05:35:57.578908+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_656523 | REC_0002980 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 33 | 15.5 | 50 | male | 0 | 7 | 5.4 | 1 | entrectinib 600 mg daily | 18.5 | false | MSS | 2026-03-15T05:35:57.579160+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_667493 | REC_0002981 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.8 | 57 | male | 1 | 47 | 4.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 5.2 | true | MSS | 2026-03-15T05:35:57.579416+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_949476 | REC_0002982 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5.5 | 62 | male | 1 | 50 | 4.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 9 | false | MSS | 2026-03-15T05:35:57.579671+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141597 | REC_0002983 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 12.7 | 67 | female | 0 | 17 | 6 | 2 | osimertinib 80 mg daily | 9.7 | true | MSI-H | 2026-03-15T05:35:57.579920+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743314 | REC_0002984 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 10.5 | 57 | female | 1 | 14 | 7.3 | 4 | osimertinib 80 mg daily | 11.5 | false | MSI-H | 2026-03-15T05:35:57.580241+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_842518 | REC_0002985 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 13.4 | 67 | female | 0 | 19 | 2.9 | 0 | osimertinib 80 mg daily | 11.5 | false | MSS | 2026-03-15T05:35:57.580492+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_979943 | REC_0002986 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 10.9 | 68 | female | 1 | 18 | 4.4 | 7 | sotorasib 960 mg daily | 15.9 | false | MSS | 2026-03-15T05:35:57.580735+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_313511 | REC_0002987 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 31 | 3.7 | 71 | female | 1 | 14 | 5.6 | 6 | pembrolizumab 200 mg q3w | 11.5 | true | MSS | 2026-03-15T05:35:57.580976+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_841176 | REC_0002988 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 10.4 | 83 | female | 2 | 14 | 6.1 | 5 | osimertinib 80 mg daily | 8.2 | true | MSI-H | 2026-03-15T05:35:57.581215+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_138584 | REC_0002989 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 31 | 5.8 | 70 | female | 2 | 60 | 3 | 6 | pembrolizumab 200 mg q3w | 13.9 | true | MSS | 2026-03-15T05:35:57.581445+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_868030 | REC_0002990 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 15.1 | 63 | female | 0 | 18 | 5.2 | 1 | sotorasib 960 mg daily | 16.6 | false | MSS | 2026-03-15T05:35:57.581682+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801153 | REC_0002991 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 15.9 | 73 | female | 1 | 1 | 5 | 2 | osimertinib 80 mg daily | 18.9 | true | MSI-H | 2026-03-15T05:35:57.582034+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_247262 | REC_0002992 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 8.2 | 66 | female | 1 | 9 | 6.6 | 4 | osimertinib 80 mg daily | 12 | false | MSS | 2026-03-15T05:35:57.582267+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_732453 | REC_0002993 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 5.5 | 74 | female | 2 | 58 | 4.5 | 8 | carboplatin + paclitaxel + pembrolizumab | 18.8 | true | MSS | 2026-03-15T05:35:57.582501+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_990067 | REC_0002994 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 34 | 12.5 | 75 | male | 1 | 9 | 7.2 | 1 | entrectinib 600 mg daily | 19.6 | true | MSI-H | 2026-03-15T05:35:57.582739+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_563800 | REC_0002995 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 20.6 | 90 | female | 2 | 22 | 6.6 | 5 | sotorasib 960 mg daily | 21.4 | false | MSS | 2026-03-15T05:35:57.582974+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664146 | REC_0002996 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 10.3 | 65 | male | 0 | 8 | 3.6 | 1 | osimertinib 80 mg daily | 11.4 | false | MSS | 2026-03-15T05:35:57.583211+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_418221 | REC_0002997 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 6.5 | 72 | female | 1 | 6 | 5.9 | 2 | entrectinib 600 mg daily | 24.2 | true | MSS | 2026-03-15T05:35:57.583447+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795167 | REC_0002998 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 20.5 | 59 | male | 1 | 17 | 4.9 | 7 | alectinib 600 mg BID | 13.6 | true | MSI-H | 2026-03-15T05:35:57.583697+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_177900 | REC_0002999 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 14.4 | 63 | female | 1 | 17 | 3.7 | 5 | sotorasib 960 mg daily | 17.6 | false | MSI-H | 2026-03-15T05:35:57.583954+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_477126 | REC_0003000 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 16.1 | 63 | male | 0 | 13 | 6.2 | 2 | osimertinib 80 mg daily | 22 | false | MSI-H | 2026-03-15T05:35:57.584259+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.